Latest & greatest articles for pravastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pravastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pravastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pravastatin

1. Pravastatin

Pravastatin Top results for pravastatin - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pravastatin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

2. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Effect of pravastatin on cardiova... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1998 ) Volume: 129 , Issue: 9 , Pages: 681-689 PubMed: Available from or Find this paper at: Abstract (...) BACKGROUND: A majority of all myocardial infarctions occur in patients who are 65 years of age or older and have average cholesterol levels, but little information is available on whether cholesterol lowering in such patients reduces the rate of recurrent cardiovascular disease. OBJECTIVE: To determine whether pravastatin reduces the rate of recurrent cardiovascular events in older patients. DESIGN: Subset analysis of a randomized, controlled trial. SETTING: 80 hospitals and affiliates in the United

Annals of Internal Medicine2013

3. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Pravastatin for secondary prevent... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2003 ) Volume: 138 , Issue: 2 , Pages: 98-104 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Cardiovascular disease is a common cause of morbidity and death in persons (...) with renal insufficiency. Although 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors (statins) are effective for secondary prevention of cardiovascular events in the general population, they have not been specifically studied in chronic renal insufficiency. OBJECTIVE: To determine whether pravastatin is effective and safe for secondary prevention of cardiovascular events in persons with chronic renal insufficiency. DESIGN: Post hoc subgroup analysis of a randomized, double-blind, placebo

Annals of Internal Medicine2013

5. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy

Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy 20816118 2010 09 06 2010 09 28 2013 11 21 1879-1913 106 6 2010 Sep 15 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. 787-92 10.1016/j.amjcard.2010.05.005 Patients with mixed hyperlipidemia and at high (...) risk of coronary heart disease may not achieve recommended low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol goals on statin monotherapy. This study was designed to evaluate the efficacy and safety of a fenofibrate 160 mg/pravastatin 40 mg fixed-dose combination therapy in high-risk patients not at their LDL cholesterol goal on pravastatin 40 mg. In this 12-week, multicenter, randomized, double-blind, double-dummy, parallel-group study, after a run

EvidenceUpdates2010

6. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance

Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance 20102918 2010 01 27 2010 02 25 2015 06 15 1879-1913 105 2 2010 Jan 15 The American journal of cardiology Am. J. Cardiol. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. 198-204 10.1016/j.amjcard.2009.08.672 Currently, no consensus has been reached regarding (...) the management of hyperlipidemia in patients who develop statin-associated myalgia (SAM). Many statin-intolerant patients use alternative lipid-lowering therapies, including red yeast rice. The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia. The study was conducted in a community-based setting in Philadelphia, Pennsylvania. A total of 43 adults with dyslipidemia and a history of statin discontinuation because

EvidenceUpdates2010

7. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) 18676075 2008 08 26 2008 09 18 2016 12 15 1523-6838 52 3 2008 Sep American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Progression of kidney disease in moderately hypercholesterolemic, hypertensive (...) patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 412-24 10.1053/j.ajkd.2008.05.027 Dyslipidemia is common in patients with chronic kidney disease. The role of statin therapy in the progression of kidney disease is unclear. Prospective randomized clinical trial, post hoc analyses. 10,060 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (lipid

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

8. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of rosuvastatin in comparison with atorvastatin, simvastatin, and pravastatin for managing lipid parameters in patients with hypercholesterolaemia. The authors

NHS Economic Evaluation Database.2008

9. Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years

Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years Article Text Treatment Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years Statistics from

Evidence-Based Nursing (Requires free registration)2008

10. Does pravastatin promote cancer in elderly patients: a meta-analysis

Does pravastatin promote cancer in elderly patients: a meta-analysis Does pravastatin promote cancer in elderly patients: a meta-analysis Does pravastatin promote cancer in elderly patients: a meta-analysis Bonovas S, Sitaras N M CRD summary This review evaluated the effect of pravastatin therapy on cancer risk, according to age. The authors concluded that pravastatin may be associated with an increased risk of cancer among elderly people, but further verification was needed. The conclusions (...) should be regarded with some caution because of limitations in the review process. Authors' objectives To evaluate the effect of pravastatin therapy on cancer risk modified by age. Searching MEDLINE (1966 to February 2006) and Science Citation Index Expanded (1970 to February 2006) were searched for papers in any language; the search terms were reported. The references of retrieved articles were also checked for additional papers. Study selection Study designs of evaluations included in the review

DARE.2007

11. Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention

Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Zhou Z, Rahme E, Pilote L CRD summary This review assessed (...) the relative efficacy of pravastatin, simvastatin and atorvastatin. The authors concluded that the evidence suggests there is no statistically significant difference in long-term cardiovascular outcomes between standard doses of these statins. Statements on relative efficacy were based on indirect comparisons, thus the authors' cautious conclusion appears appropriate. Authors' objectives To assess the relative efficacy of pravastatin, simvastatin and atorvastatin. Searching MEDLINE and the Cochrane

DARE.2006

12. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK

Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Davies A, Hutton J, O'Donnell J, Kingslake S Record Status This is a critical abstract (...) rosuvastatin (ROS), atorvastatin (ATO), simvastatin (SIM), pravastatin (PRA) and fluvastatin (FLU). Initial doses were 10 mg for ROS, ATO and SIM, 20 mg for PRA, and 40 mg for FLU. Patients who failed to reach the target cholesterol level with the initial dosage where titrated to the next highest dosage (20 and 40 mg for ROS and PRA, 20, 40 and 80 mg for ATO and SIM, and 40 and 80 mg for FLU). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

NHS Economic Evaluation Database.2006

13. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. 17011942 2006 10 02 2006 10 12 2015 06 16 1474-547X 368 9542 2006 Sep 30 Lancet (London, England) Lancet Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. 1155-63 Evidence-based treatment for hypercholesterolaemia in Japan has been hindered by the lack of direct evidence in this population (...) . Our aim was to assess whether evidence for treatment with statins derived from western populations can be extrapolated to the Japanese population. In this prospective, randomised, open-labelled, blinded study, patients with hypercholesterolaemia (total cholesterol 5.69-6.98 mmol/L) and no history of coronary heart disease or stroke were randomly assigned diet or diet plus 10-20 mg pravastatin daily. The primary endpoint was the first occurrence of coronary heart disease. Statistical analyses were

Lancet2006

14. High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome

High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High dose atorvastatin was superior to standard dose pravastatin in reducing death or major CV events in acute coronary syndrome Article Text Therapeutics High dose atorvastatin was superior to standard dose pravastatin in reducing death or major

Evidence-Based Medicine (Requires free registration)2005

15. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial

Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin (...) , pravastatin and simvastatin: analysis of the STELLAR trial Hirsch M, O'Donnell J C, Jones P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rosuvastatin (10 - 40 mg/day), atorvastatin (10 - 80 mg/day), pravastatin (10 - 40 mg

NHS Economic Evaluation Database.2005

16. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan

Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of pravastatin (20 mg/day) for the primary prevention of coronary heart disease (CHD). A dose of 10 mg/day pravastatin was also considered for a different sub-group of patients. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of Japanese men

NHS Economic Evaluation Database.2005

17. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial)

Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared (...) with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial) Miller P S, Smith D G, Jones P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use rosuvastatin (10, 20 or 40 mg) in the treatment of patients

NHS Economic Evaluation Database.2005

18. Pravastatin lowered coronary disease risk in elderly persons with or at risk of vascular disease

Pravastatin lowered coronary disease risk in elderly persons with or at risk of vascular disease Pravastatin lowered coronary disease risk in elderly persons with or at risk of vascular disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pravastatin lowered coronary disease risk in elderly persons with or at risk of vascular disease Article Text Therapeutics Pravastatin lowered coronary disease risk in elderly persons with or at risk of vascular disease Free Edward Havranek , MD Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Medicine (Requires free registration)2004

19. Pravastatin was not better than usual care in reducing all cause mortality or CHD events

Pravastatin was not better than usual care in reducing all cause mortality or CHD events Pravastatin was not better than usual care in reducing all cause mortality or CHD events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pravastatin was not better than usual care in reducing all cause mortality or CHD events Article Text Therapeutics Pravastatin was not better than usual care in reducing all cause mortality or CHD events Free Arthur T Evans , MD, MPH , Brian P Lucas , MD Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Medicine (Requires free registration)2004

20. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective

Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective Glasziou P P, Eckermann S D, Mulray S E (...) , Simes R J, Martin A J, Kirby A C, Hall J P, Caleo S, White H D, Tonkin A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared cholesterol-lowering therapy with pravastatin with no therapy (i.e. placebo). Type

NHS Economic Evaluation Database.2002